{
    "clinical_study": {
        "@rank": "95576", 
        "acronym": "PAPALDO", 
        "arm_group": [
            {
                "arm_group_label": "Subcutaneous GCSF 5 \u00b5g/kg days 8 and 12", 
                "arm_group_type": "Experimental", 
                "description": "Prophylactic administration of GCSF on days 8 and 12 following chemotherapy"
            }, 
            {
                "arm_group_label": "No intervention", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile\n      neutropenia among patients with breast cancer, treated with chemotherapy and presenting with\n      a low to moderate risk of developing febrile neutropenia."
        }, 
        "brief_title": "Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neutropenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Breast cancer Chemotherapy administration (new line) Chemotherapy type : FEC, EC, AC,\n        docetaxel containing regimen Chemotherapy setting : adjuvant or neoadjuvant\n\n        Exclusion Criteria:\n\n        Eligibility to receive reimbursed GCSF"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "142", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01658956", 
            "org_study_id": "Institut Jules Bordet"
        }, 
        "intervention": {
            "arm_group_label": "Subcutaneous GCSF 5 \u00b5g/kg days 8 and 12", 
            "intervention_name": "GCSF administration on days 8 and 12 after chemotherapy", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Lenograstim"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GCSF", 
            "Chemotherapy", 
            "Breast cancer", 
            "Prophylaxis"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "aspasia.georgala@bordet.be", 
                "last_name": "Aspasia Georgala, MD", 
                "phone": "3225413255"
            }, 
            "contact_backup": {
                "email": "marianne.paesmans@bordet.be", 
                "last_name": "Marianne Paesmans", 
                "phone": "3225413399"
            }, 
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1000"
                }, 
                "name": "Institut Jules Bordet"
            }, 
            "investigator": {
                "last_name": "Aspasia Georgala, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of a febrile neutropenic episode defined as fever (>=38.5\u00b0C once or >=38\u00b0C twice within 12 hours interval) and neutropenia (ANC < 0.5 IU)", 
            "safety_issue": "No", 
            "time_frame": "At the beginning of 2nd chemotherapy cycle, no more than 30 days after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01658956"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Unplanned hospitalization is defined as the need to admit a patient outside of the schedule that was planned for chemotherapy administration", 
                "measure": "Need for unplanned hospitalization", 
                "safety_issue": "Yes", 
                "time_frame": "At the beginning of second chemotherapy cycle, no more than 30 days after randomization"
            }, 
            {
                "description": "A complicated febrile neutropenic episode is defined as a febrile neutropenic episode (see above) that does not resolve without the occurrence of serious medical complication as defined in Klasterky J et al; JCO 2000 : 3038-3051", 
                "measure": "Complicated febrile neutropenic episode", 
                "safety_issue": "No", 
                "time_frame": "At the beginning of the second chemotherapy cycle, no more than 30 days after randomization"
            }, 
            {
                "measure": "Mortality any cause", 
                "safety_issue": "Yes", 
                "time_frame": "30 days from randomization"
            }
        ], 
        "source": "Jules Bordet Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jules Bordet Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}